Inclusive Health Research

Building Global Health Equity Together

In partnership with Takeda.

Illustration by Sam Falconer.

Illustration by Sam Falconer.

The Inclusive Health Research awards have been established by Nature Awards in partnership with Takeda to celebrate those who are driving a more inclusive approach to health research and, in doing so, promote a future of greater health equity globally. 

About the programme

Aims & scope

Health research needs to happen in collaboration. In order to develop new, diverse and sustainable health solutions, dialogue and participation are needed to ensure that key voices are heard and perspectives are considered when deciding what direction the scientific journey will take.  

Inclusive health research is an approach where positive, respectful engagement occurs between researchers and key affected stakeholders and organizations during the lifecycle of a research project such that the research is more likely to yield appropriate, sustainable, cost-effective, accessible solutions and these individuals and groups have a greater sense of shared ownership of the process and the outcomes. 

For example, engagement may occur with patients, carers, local clinicians, scientists, experts, or patient and community/civil society groups in affected communities to ensure that there is a clear understanding of the needs, priorities, and wishes of those communities. 

Equally, there could be involvement of patients, affected communities or their representatives, health or scientific experts in the design and delivery of research to build buy-in, key relationships, trusted partnerships and as a byproduct, transfer skills and knowledge in both directions. 

Finally, building relationships with key stakeholders such as corporates, non-governmental organizations, healthcare providers and government departments in order to access resources, expertise and the support required to translate the research towards positive health impact.

The Inclusive Health Research awards aim to:

  • Uncover innovation and best practice in inclusive health research that has been influenced by engagement with affected communities and their expert representatives.
  • Recognize, promote and support institutions and individuals who are contributing to a diverse, patient- and affected community-inclusive research ecosystem.
  • Build a library of case studies to share — and encourage wider adoption of — new ideas and best practice in the co-production of research to advance global health equity.

Health equity

“When every person has the opportunity to attain his or her full health potential and no one is hindered from achieving this potential because of social position or other socially determined circumstances.”

To enter, write a case study telling us about the inclusive approach you take to your work and how it has or might lead to better outcomes and greater health equity. Ideally, co-author it with your partners.

We will provide three prizes, each of 20,000 €, to the best entries as selected by our panel of expert judges. The funds must be used in line with the spirit and goals of this award to develop a more inclusive health research ecosystem. As such it can be used to support the development of the project towards positive impact.

Key dates

  • 13th September 2022: Applications open
  • 6th January 2023: Applications close
  • May 2023: Shortlist announced
  • July 2023: Winner announced

Eligible applicants

We welcome entries from anyone directly engaged in activities connected to health research and especially those located in low- and middle-income countries (LMICs), and/or representing under-served communities. We encourage applications from a range of organizations and individuals within them. Applications are to be led by someone who has played a key role. Approval will be needed by key partners. Eligible applicants can include:

  • Individual researchers, clinicians or research groups based at public or private institutions
  • Patient advocacy and representative groups
  • Health charities
  • Health research funders
  • Health research publishers
  • Companies
  • NGOs
  • Government departments

Eligible activities

We are seeking a diverse range of applications demonstrating inclusive thinking and action during the health research process. The project must have occurred within ten years of the application deadline, i.e., the 6th January 2013.

Projects do not need to be initiated by researchers, but may be the result of engagement initiated and developed by any of the eligible entities previously listed. Collaborations and initiatives within and across the public and private sectors are welcome. We are looking for examples which demonstrate best practice as well as new and innovative approaches. 

We are particularly keen to receive applications in relation to:

  • Historically under-served patient groups and communities.
  • Low- and middle-income countries (LMICs), i.e., countries identified by the Organisation for Economic Co-operation and Development (OECD) as having low-income or middle-income economies.

Award categories & prizes

Three categories have been created to enable projects that are at different stages of the research process to enter and be evaluated against those that are at a similar level of development.

The table below provides an overview of example eligible activities in the three award categories. Applications are not expected to include all activities. Applications in category two and three can include information on activities that were conducted earlier in the project.

One winner will be selected by our panel of expert judges in each category and will receive a prize of 20,000 €, plus coverage on (the format and amount to be determined at the sole discretion of Springer Nature). A winner will be selected from each category as long as the standard of applications is sufficiently high.

Understanding needs and context

Engagement to identify health needs of patient populations/ affected communities and key contextual information to inform research questions and potentially design interventions.

How patient views and priorities are considered in selecting research priorities. 

How health equity issues might inform which unmet health needs to investigate.

How research funder priorities are established, budgets allocated and relevant projects selected.

Designing and conducting research

How health research is designed to address clearly identified unmet patient and community needs, and the relevant healthcare environment, in order to maximize the chance of success of solutions.

Appropriate involvement of patients, representatives, and experts in the design and delivery of research to build buy-in, key relationships and trusted partnerships.

Appropriate involvement of a range of experts to transfer skills and knowledge in both directions.

Translating research to impact

Proactive engagement in order to develop the findings after the key research has been conducted. 

Building relationships with key stakeholders in order to access resources, expertize and the support required to translate the research towards positive health impact and to hand over leadership of the project when required.

Appropriate involvement of patients, etc. in translation of results.

Acknowledging the role that other parties played in the course of communicating findings.

What are we looking for?

The main part of the application takes the form of a case study.

We expect that case studies will fall into two broad formats:

  1. Health need — focused on a specific patient population or community and associated unmet health needs
  2. More inclusive research ecosystem — focused on initiatives relating to changes in policies or working practices that support a more inclusive health research ecosystem, particularly — but not limited to — funding practices, publishing, communicating and other framing activities.

Case studies will be evaluated on the basis of evidence appropriate to the case study and include:

  • Inclusivity and engagement with patients, affected communities and their representatives
  • Clear identification of specific health needs
  • Relationship building to support co-production of research and sense of ownership by community stakeholders and/or partners 
  • Advocacy of inclusive approaches and culture change within teams and organizations 
  • Targeting historically under-served communities and patient groups
  • Development and adoption of best practice or innovative/disruptive approaches

Additional weighting will be given to applications from low- and middle-income countries  (LMICs) as defined by the OECDUN.

More detailed information is available here.


How to apply

Applications for this award are now closed.

Guidelines for applicants pdf download.

Download Guidelines for applicants as a pdf.

Download Guidelines for applicants as a pdf.

Terms & conditions

By submitting an application you agree that: You have read and accepted the award terms and conditions and your personal data will be used as part of, and to communicate with you about, the Nature Awards programme. You can remove your details by emailing For more information view our Privacy Policy.

Key dates

  • 13th September 2022: Applications open
  • 6th January 2023: Applications close
  • May 2023: Shortlist announced
  • July 2023: Winner announced


Please contact us at if you require any further information.


Héctor H. García.

Héctor H. García, M.D., Ph.D., is Director of the Center for Global Health and Professor in the School of Sciences at the Universidad Peruana Cayetano Heredia, as well as head of the Cysticercosis Unit at the Instituto Nacional de Ciencias Neurologicas in Lima, Peru, and an Adjunct Professor at the Johns Hopkins Bloomberg School of Public Health in Baltimore, MD, USA. He earned his Ph.D. in 2002 from The Johns Hopkins University Bloomberg School of Public Health and his M.D. in 1989 from The Universidad Peruana Cayetano Heredia in Lima, Peru. He was a senior international research fellow of The Wellcome Trust, UK, and was awarded the Christophe and Rodolphe Merieux Prix from the Merieux Foundation and the Institut de France in 2011.

Hector is one of the foremost researchers worldwide in the study of neurocysticercosis, a preventable parasitic infection of the central nervous system caused by the pork tapeworm Taenia solium. He has a long history in global health research and training, including the successful direction of a 10‑year cysticercosis elimination program in northern coastal Peru, funded by the Bill & Melinda Gates Foundation. He leads the Cysticercosis Working Group in Peru, a multi-institutional group working in varied aspects of cysticercosis research. His lab has over 380 peer-reviewed publications in diverse subjects of public health importance in Peru.

Hamied Haroon.

Hamied Haroon is a Research Associate in Biomedical Magnetic Resonance Imaging (MRI) at The University of Manchester. He is an active campaigner for the rights of disabled staff and Chair of the National Association of Disabled Staff Networks (NADSN), which has become a hub for disabled people working in universities and other organisations across the UK.

Akin Jimoh.

Akin Jimoh is a medical physiologist, health communication expert, journalist and journalism trainer. He was a communication specialist with UNICEF Nigeria (2013 to August 2017); a Knight Fellow at MIT (1999/2000) and a Bell Fellow at Harvard (1995/96). Currently he is the Chief Editor of Nature Africa.

Dr Abhilasha Karkey.

Abhilasha Karkey, an Associate Professor of Oxford University, is a medical microbiologist involved in clinical research at Oxford University Clinical Research Unit Nepal. The research unit is embedded within the Patan Academy of Health Sciences and based in Patan Hospital, Kathmandu. She has a DPhil from the University of Oxford and an MSc in Medical Microbiology from the University of Liverpool. Her research primarily focuses on the development and transmission of antimicrobial resistance in hospital and community settings, particularly among Gram-negative pathogens: Klebsiella pneumoniae and Enterobacter spp. Abhilasha has over a decade of experience working with Médecins Sans Frontières (MSF) often in very difficult conflict areas. She utilizes her expertise and experience in helping to build a strong and critical scientific community and establish a scientific research culture in Nepal.

Abhilasha was an OAK Scientific Leadership Fellow, an Aspen New Voices and Alan J. Magill Fellow.

Ellos Lodzeni.

Ellos Lodzeni is a Global Patient, Health, Governance and Social Justice advocate from Malawi and also a WHO Patient for Patient Safety Champion suffering from a range of chronic diseases with some Family members suffering from Diabetes and mental health. A holder of a Bachelor of Arts Public Administration (Credit) from Chancellor College of the University of Malawi and also a Master of Arts (Development Studies) obtained from the University of East Anglia, UK. He is a retired Public Servant having worked in various Malawi Government Ministries for 35 years including Ministry of Health and Executive Secretary of Office of the Malawi Ombudsman.

He was elected as Vice Chairperson of the International Alliance of Patients Organizations (IAPO) on 9th September 2022, and has been the Board Member and Treasurer of IAPO from 1st August 2018 and just re-elected for another three year term in March 2022. He is a Founder Trustee for Geneva based IAPO Patient for Patient Safety Observatory (IAPO-P4PS) with effect from October 2020, Advisory Board Member for University of York Thanza La Onse (TLO)/IAPO Health research partnership since June 2021 and now Advisory Board Member for Eu funded Better E-Health Project with implementation Hubs in Tunisia, Ghana, Ethiopia and Malawi.

Karen O’Leary.

Karen O'Leary received her undergraduate degree in microbiology from University College Cork, followed by an MSc in biomedical science from Edinburgh Napier University. She then joined the University of Cambridge Department of Haematology as a research assistant, before moving to the University of Sussex to pursue her doctoral studies on lung cancer epigenetics with Peter Schmid. Karen then worked as a postdoc with Sharon Glynn at the National University of Ireland, Galway, studying the interaction of prostate cancer cells and stromal cells, before going on to expand her knowledge of translational and clinical science while working as a writer at a medical communications agency. Karen joined Nature Reviews Cancer as a Locum Associate Editor in 2020, and joined Nature Medicine in 2021, where she oversees research analysis content, including Reviews, Perspectives, News & Views and Research Highlights.

Subhra Priyadarshini.

Subhra Priyadarshini is the chief editor of Nature India and co-chair of Springer Nature’s employee network SN Women. In both her roles, she leads a number of diversity, equity and inclusion (DEI) activities, specially focused on women in science and science publishing. Through Nature India’s outreach activities, Subhra trains scientists and health professionals in effective science communication. She has mentored the FameLab competition to hunt for the best science communicators in India and helms the Nature India-Wellcome Trust Science Media Fellowships. Subhra also trains health and medical journalists at a Google News supported initiative to combat medical misinformation.

Magdalena Skipper.

Magdalena Skipper is editor in chief of Nature. She is a geneticist by training. She did her doctoral work at the MRC Laboratory of Molecular Biology, Cambridge, UK followed by a postdoctoral fellowship at CRUK in London, UK. She has considerable editorial and publishing experience: having started in Nature Publishing Group in 2001, she was chief editor of Nature Reviews Genetics, senior editor for genetics and genomics at Nature, and more recently editor in chief of Nature Communications. She is passionate about mentorship, transparent science and positive research culture.

Sophie Staniszewska leads the Patient and Public Involvement and Engagement (PPIE) and Experiences of Care Research Programme at Warwick Medical School, UK. She undertakes studies exploring the patient and public experiences of health care and is developing the concept of patient-based evidence. She is also developing the evidence base of PPIE in areas such as mathematical and economic modelling, genomics and enabling data and gastrointestinal infections.

Richard Stephens.

Richard Stephens has been a patient advocate for over two decades and has sat on and chaired strategic groups in the UK and Europe, as well as working on individual research studies as a patient partner. He also works with industry and with patient groups in Europe, Canada and the USA. He helped found the AllTrials campaign and useMYdata movement, and he is the founding co-Editor-in-Chief of the Journal of Research Involvement and Engagement.

Richard has survived two cancers, a heart emergency, and continued co-morbidities and late effects. He has participated in four interventional studies and nine others.

Joshua Vogel.

Joshua Vogel is a medical doctor with a PhD in maternal and perinatal epidemiology. His research work focuses on improving the health and well-being of women and families living in resource-constrained settings. Since 2012, he has co-ordinated and contributed to a number of WHO-led primary research, knowledge synthesis and implementation activities in low and middle-income countries. His areas of professional interest are the quality of antenatal and intrapartum care, stillbirth prevention and preterm birth management. He has extensive experience in clinical epidemiology, interventional research, systematic reviews and guideline development. Joshua is a lead investigator on the WHO ACTION Trials (Antenatal Corticosteroids for Improving Outcomes of Preterm Newborns), two multi-country randomized controlled trials evaluating the efficacy of antenatal corticosteroids in hospitals in five low-resource countries. He is also the lead investigator on a six-country study evaluating the new WHO Labour Care Guide for labour and childbirth management. He has led the development of several WHO guidelines, and established WHO’s first ‘living guidelines’ in maternal and perinatal health.

Miyoko O. Watanabe.

Miyoko O. Watanabe is Senior Fellow at Japan Science and Technology Agency (JST). She is also President of NPO WoodDeck in Japan, and Director of Nihon University. Dr. Watanabe is a member of the Science Council of Japan and chair of the council’s Committee on Gender-based Innovation. She is also a member of Committee at Ministry of Education, Culture, Sports, Science and Technology, as well as a member of Committees at Ministry of the Environment in Japan. She serves at Cabinet Office in Japan as STEM girls ambassador. She has a long experience of research in semiconductor physics at Toshiba R&D Center in Japan since 1979.

Frequently asked questions


Q: Who can I contact for more information?

Please don’t hesitate to contact us if you require any further information at

Q: What do you mean by ‘inclusive health research’? 

A: We define ‘inclusive health research’ as an approach to human health research where positive, respectful engagement occurs between researchers and key affected stakeholders and organizations during the lifecycle of a research project such that the research is more likely to yield appropriate, sustainable, cost-effective, accessible solutions and these individuals and groups have a greater sense of shared ownership of the process and the outcomes. Engagement occurs with patients, carers, local clinicians, scientists, experts, and patient and community/civil society groups in affected communities to ensure that there is a clear understanding of the needs, priorities, and wishes of patients. There is appropriate involvement of patients or their representatives, health or scientific experts in the design and delivery of research to build buy-in, key relationships, trusted partnerships and, as a byproduct, transfer skills and knowledge in both directions. Finally, building relationships with key stakeholders such as corporations, NGOs, healthcare providers and government departments in order to access resources, expertise and the support required to translate the research towards positive health impact.

Q: What academic disciplines are included in the definition of health research? 

A: We define health research as any research which ultimately aims to improve human health and as such any academic discipline could play a role in providing insights that lead to the provision of better healthcare interventions. However, applications focused on academic research relating to the topic of inclusive health research itself are not eligible. 

Q: Is animal health also eligible? 

A: Not at present. This award is currently focused on human health. If animal research has led to insights that are highly relevant to human health and the research has been refocused on human health, this is eligible. 

Q: Is it mandatory that the applicant or colleagues must have spoken to patients or members of an affected community?

A: Not necessarily, but active and respectful engagement is central to this award and key in the evaluation process. There must have been engagement with individuals or organizations that act as patient representatives, or are experts in relation to the condition and improving health outcomes and who to have such dialogue directly with affected communities, i.e., patient advocacy groups, healthcare professionals (general practitioners, clinicians, nurses, etc.), NGOs, health research charities, etc. 

Q: Do we have to demonstrate inclusivity throughout the project?

A: No, but applications demonstrating early and sustained inclusivity will score more highly. 

Q: Does the application have to be focused on developing a specific health intervention such as diagnostic, drug or medical device? 

A: No. We appreciate that research may be focused on understanding more about health needs or disease pathology, epidemiology, etc. and that the findings may not directly lead to a specific intervention. 

Q: Can an individual, partnership or organization be involved in more than one application? 

A: Yes, but the initiatives that each application relates to should be different. 

Q: Are there any requirements as to when the project took place? 

A:The activity detailed in the case study must have occurred within ten years of the application deadline, i.e., 6th January 2013. 

Q: Do you have to be a researcher to apply? 

A: No. If your application relates directly to an individual research project, you must have played a significant role in the project and have the approval of the research team and other key partners, but do not need to be an active researcher yourself. 

Q: Who is awarded the prize? 

A: We accept applications from organizations, departments, individuals (of any gender) or project teams. The winner is not the lead applicant but is the project/initiative as a whole. The applicant acts as a representative. It is unlikely that a single individual working in isolation will be selected as the winner.

Q: Are there conditions on how the prize money must be used and over what time frame? 

A: The funds must be used in line with the spirit and goals of this award to develop a more inclusive health research ecosystem. As such it can be used to support the development of the project towards positive impact. It is not to be used to fund overheads, general lab or organizational activities. It must be spent within a year of receipt. A brief report will be required within a year detailing how the funds were utilized. You may also be required to give a short presentation to representatives of the sponsor. If there is any disagreement between the partners, the lead applicant can decide how to utilize the funds. 

Q: If our application is shortlisted and published by Springer Nature, can we publish the case study text elsewhere?

A: Yes. 

Q: If my institution has received funding from Takeda, or has a partnership with them, can I apply? 

A: If funding was received by your institution for an unrelated project, or there is a partnership in place in relation to a different project, then you can apply. If the lead applicant or partners have received funding from Takeda for this specific project or have a collaboration, then they are not eligible. 

Q: Can Takeda be one of the partners involved in the application? 

A: No. 

Q: If our entry is selected for the shortlist, can we edit the application before publication as a case study?

A: We encourage you to produce an application that can be published as it is. Our team will conduct proofreading and copyediting. In some cases we may restructure the case study content. You may be asked for some edits but will not be able to approve the final text.


Q: Who is eligible?

A: Anyone currently in a role that relates directly to health research.

Q: Do applicants need to be nominated?

No. Applicants for each award do not need to be nominated. However, you can recommend an applicant here. They will be sent an email once they have been recommended directing them to apply.

Q. If an applicant is shortlisted in the first cycle of the programme, are they eligible to apply for the award again?

Previous applicants are more than welcome to re-apply but there should be a significant change in the progress of the project/initiative to justify a resubmission.


Q: How do I apply?

Applications for this award have now closed.

Q: When can I apply?

Applications open on the 13th September 2022 and close on the 6th January 2023.

Q: When will I know if I have been shortlisted?

All shortlisted applicants will be contacted in April 2023.

Q. Will I receive updates on my application?

Unfortunately, we cannot provide individual feedback on applications. Successful applicants will be contacted by the dates indicated.


In partnership with Takeda.

About Takeda

Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.

For more information, visit

About the Takeda Center for Health Equity and Patient Affairs (HEPA)

Through the Takeda Center for Health Equity and Patient Affairs (HEPA), launched in 2020, Takeda is collaborating with diverse partners, including patients, communities and organizations, as well as public and private organizations, to identify and address health inequities in communities. Within Takeda, HEPA sits at the intersection of research and access activities, serving as a center of excellence to all business units. Equity starts with understanding. Once we understand diverse patients’ needs and the communities in which they were born, grow, live, work and age, we can create more inclusive practices and develop innovative medicines that better reflect how patients wish and need to engage with healthcare to achieve their highest level of health.


Terms & conditions

1. Inclusive Health Research

Please read these terms and conditions carefully. By entering the Nature Awards for Inclusive Health Research (the “Programme”) you agree that you have read and agree to these terms and conditions (the “Terms”). The Terms include the prize details and all instructions on how to participate or take part in the Programme. Failure to comply with the Terms may result in disqualification from participation in the Programme.

2. Parties

The Programme is run by Springer Nature Limited, a company registered in England and Wales, registered number 00785998 and registered office at The Campus, 4 Crinan Street, London N1 9XW, under their brand name Nature Awards, in collaboration with Takeda, Development Center Americas, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, a company incorporated in the USA whose principal place of business is at 95 Hayden Avenue, Lexington, MA, 02421 USA (together, the “Promoter”).

3. Eligibility

To be eligible to enter the Programme, the participant must:

  1. Be engaged in an activity directly connected to health research;
  2. Have actively and respectfully engaged or partnered with affected populations in the course of that activity.

4. Criteria for programme submission

  1. Participants will be required to prepare a case study describing their programme.
  2. Participants will also need to provide personal/organization details and a shortlist profile. Full details are available in the guidelines for applicants.
  3. Participants must apply via the application form.
  4. Applications should be in English.
  5. Entries must be complete and submitted online with all relevant supporting materials. Entries can be submitted between 12 noon BST on the 13th September 2022 and 12 noon GMT on the 6th January 2023.

5. Exclusions

  1. Please note that the Programme is not open at any stage to:
    1. persons resident in countries or territories where local, state, provincial or national laws prohibit the promotion of, operation of or participation in such awards or receiving prizes pursuant to the Programme;
    2. persons resident in Cuba, Iran, North Korea, Sudan, Syria, Burma/Myanmar, the Crimea region of Ukraine or other sanction-sensitive countries or regions as updated from time to time;
    3. any individual named on Specially Designated Nationals lists as updated from time to time;
    4. directors or employees (or members of their immediate families) of the Promoter or any affiliate of the Promoter;
    5. any current members of the judging panel or ambassadors (or members of their immediate families);
  2. Applications received after the deadline will not be accepted.
  3. Complete submissions must be in English and include all sections requested by the Promoter.
  4. Incomplete submissions may be declared ineligible, and participants may not be given the opportunity to re-submit or alter their submission.

6. Review and shortlisting process

  1. An expert panel convened by The Promoter will review all submissions. The panel will exclude those which are not eligible. The panel will select a shortlist of outstanding submissions which will be featured in the Inclusive Health Research Case Study Library.
  2. The shortlisted participants will be notified on or before 30th April 2023. The final number of shortlisted participants is decided at the discretion of the Promoter. The Promoter reserves the right to reduce the number of shortlisted participants in the event that there are insufficient entries or that the entries are not suitable or of an unsatisfactory standard.
  3. The Promoter will select from the shortlisted participants one winner in each of the three award categories. Each category winner will receive an honorarium of 20,000 €.
  4. The panel members will make up 100% of the votes. Any decision will be final and binding and no further communication will be entered into in relation to it.
  5. Nature Awards Programme actively encourages submissions from countries in the United Nations Development Programme’s (UNDP) Country Classification System. Note that a number of weighting points will be added to such submissions, based on the country of origin’s position in the classification. Fundamental excellence and achievement remain the overriding consideration of the judges but the weighting points will be used to ensure that these are viewed in the context of the entrant’s access to opportunity and resources.

7. Honoraria

  1. The honoraria (“Honoraria”) for the Programme consists of the following:
    1. 20,000 €;
    2. coverage within (the format and amount to be determined at the sole discretion of Springer Nature).
  2. The Programme and the Honoraria are non-transferable and non-negotiable.
  3. Selected participants will be required to formally accept their Honoraria via email within 14 calendar days, and may be required to provide confirmation of eligibility. If a participant does not accept the Honoraria within 14 calendar days of being notified, they may forfeit the Honoraria and the Promoter reserves the right to choose another participant.
  4. The judges’ decision is final and the Promoter reserves the right not to correspond on any matter.
  5. Any government officials who enter the Promotion are responsible for ensuring that they may enter and/or receive an honorarium if they win, and that the honorarium does not exceed the relevant limit for their role and jurisdiction. If a shortlisted participant is not able to accept the honorarium, then in the absolute discretion of the Promoter, a charity donation may be made instead to a Promoter-approved charity.
  6. Selected participants will be required to provide their bank details, and the prize will be paid into that account. The participants are fully responsible for any tax that may be liable on the honorarium.

8. Privacy and publicity

  1. All personal data regarding participants is subject to and will be treated in a manner consistent with Springer Nature’s Privacy Policy, accessible at
  2. By participating in the Programme, your personal data will be used as part of, and to communicate with you about, the Springer Nature programme and any events which are linked to the programme. You can remove your details by emailing
  3. Applicants agree that Promoter may collect and use their personal information, which shall be shared with the judging panel which may include members outside of the Promoter’s staff, and stored until 31st December 2025, or for a further period of 2 years for shortlisted participants.
  4. By participating in the Programme, participants acknowledge that they have read and accepted the Promoter’s Privacy Policy which shall be deemed to be applicable to the Programme application.
  5. The application form used for the Programme is hosted by Submittable. By participating in the Award, participants give their consent to, such use, processing, and transfer as required by all applicable data protection laws and have sole responsibility for the accuracy, quality and legality of personal data processed by Submittable in the provision of the services they provide to the Promoter for the application process. The Submittable Privacy Policy is available at:
  6. The shortlisted participants and winners must participate in webcasts, interviews and contribute content after the award results have been announced, at the reasonable request of the Promoter.
  7. All shortlisted participants must answer profile questions and provide a headshot photograph to the Promoter as part of their application. The profile and questions will be used by the Promoter on the Award’s website. The name, region of residence, profile and likeness of shortlisted participants may be used by the Promoter for Award and event publicity in any form including on the Promoter’s website and social media pages, and those of the Sponsor, at no cost to the Promoter or Sponsor.
  8. Each shortlisted applicant shall keep the status and the listing for the Award completely confidential until after the public announcement of the shortlist by the Promoter.

9. Miscellaneous

  1. No purchase is necessary to apply for the Programme.
  2. The Promoter accepts no responsibility for any entries that are incomplete, illegible, corrupted or fail to reach the Promoter by the closing date for any reason. Proof of posting or sending is not proof of receipt. Entries via agents or third parties are invalid. No other form of entry is permitted. Please keep a copy of your entry as we will be unable to return entries or provide copies.
  3. The Promoter may, in its sole discretion, disqualify any applicant found to be tampering or interfering with the entry process or operation of the Programme website, or to be acting in any manner deemed to be disruptive of or prejudicial to the operation or administration of the Programme or otherwise in a manner not in keeping with the Promotor’s standards around ethics and research integrity.
  4. The Promoter reserves the right to withdraw the Programme and/or Honoraria from any winner or shortlisted applicant in the event that the Promoter reasonably suspects: any error in the applicant’s application form; any problem with the research programme to which the application relates; or that the applicant has acted in a manner inconsistent with the Promoter standards around ethics and research integrity.
  5. The Promoter may, in its sole discretion, withdraw the Programme and/or Honoraria from any shortlisted applicant in the event that the shortlisted applicant behaves in such a way as to bring the name or reputation of the Promoter or the Programme into disrepute.
  6. Other than for death or personal injury arising from negligence of the Promoter, so far as is permitted by law, the Promoter hereby excludes all liability for any loss, damage, cost and expense, whether direct or indirect, howsoever caused in connection with the Programme. All activities are undertaken at the applicant’s own risk.
  7. The Promoter reserves the right to cancel or amend these Terms and Conditions or change the Honoraria (to one of equal or greater value) in its discretion. No cash equivalent to the Honoraria is available.
  8. These terms and conditions shall be governed by and construed in accordance with English law. Disputes arising in connection with this Agreement shall be subject to the exclusive jurisdiction of the English courts.

Last updated: 13th January 2023.